Skip to main content
. 2020 Feb 12;22(2):e17194. doi: 10.2196/17194

Table 1.

Baseline characteristics of participants.

Characteristic Intervention group (n=37) Comparison group (n=61) P valuea
Age (years), mean (SD) 67.2 (10.4) 68.8 (9.5) .43
Gender (female), n (%) 25 (68) 41 (67) >.99
Race/ethnicity, n (%)

>.99

White non-Hispanic/Latino 35 (95) 59 (97)

Asian non-Hispanic/Latino 1 (3) 1 (2)

Unknown 1 (3) 1 (2)
Insurance type, n (%)

.55

Medicaid 3 (8) 9 (15)

Medicare 26 (70) 37 (61)

Commercial 8 (22) 15 (25)
Diabetes, n (%) 20 (54) 35 (57) .91
Hemoglobin A1c <7%,b n (%) 7 (35) 19 (54) .27
Congestive heart failure, n (%) 8 (22) 15 (25) .93
Chronic obstructive pulmonary disease, n (%) 5 (14) 9 (15) >.99
Coronary artery disease, n (%) 8 (22) 11 (18) .86
Blood pressure control <140/<90,c n (%) 26 (72) 31 (67) .81
Statin prescribed within 3 months of baseline, n (%) 27 (73) 34 (56) .14
Renin-angiotensin system inhibitors prescribed within 3 months of baseline (%) 20 (54) 22 (36) .13
Baseline albumin,d mean (SD) 4.0 (0.4) 3.9 (0.5) .44
Baseline eGFR,e mean (SD) 19 (6) 21 (5) .17

aFrom two-sample t tests or nonparametric alternatives for numerical variables and from chi-square tests for categorical variables, comparing intervention with comparison groups.

bFor diabetic patients with A1c values recorded within 90 days of baseline (intervention group: n=20; comparison group: n=35).

cFor patients with blood pressure measured within 90 days of baseline (intervention group: n=36; comparison group: n=46).

dFor patients with blood albumin measured within 90 days of baseline (intervention group: n=36; comparison group: n=56).

eFor patients with glomerular filtration rate (GFR) measured within 90 days of baseline (intervention group: n=36; comparison group: n=44).